Evidence map›Paper›PMID 41819783›Full record

ArticleRedox biology2026

PHB2 ameliorates ferroptosis and aortic aneurysm/dissection through NEDD4L-dependent ubiquitination of NCOA4.

Shengjun Xiong, Jie Lin, Ying An, Yuxin Du, Yiran E Li, Zunhui Du, Rongjun Zou, Miyesaier Abudureyimu, Junbo Ge, Yingmei Zhang and 1 more

Abstract read
In one paragraph

Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Shengjun XiongDepartment of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; National Health Commission (NHC) Key Laboratory of Ischemic Heart Diseases, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China; Key Laboratory of Viral Heart Diseases, National Health Commission, Shanghai, China.
Jie LinDepartment of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; National Health Commission (NHC) Key Laboratory of Ischemic Heart Diseases, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China; Key Laboratory of Viral Heart Diseases, National Health Commission, Shanghai, China.
Ying AnDepartment of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; National Health Commission (NHC) Key Laboratory of Ischemic Heart Diseases, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China; Key Laboratory of Viral Heart Diseases, National Health Commission, Shanghai, China.
Yuxin DuDepartment of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; National Health Commission (NHC) Key Laboratory of Ischemic Heart Diseases, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China; Key Laboratory of Viral Heart Diseases, National Health Commission, Shanghai, China.
Yiran E LiDepartment of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; National Health Commission (NHC) Key Laboratory of Ischemic Heart Diseases, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China; Key Laboratory of Viral Heart Diseases, National Health Commission, Shanghai, China.
Zunhui DuDepartment of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; National Health Commission (NHC) Key Laboratory of Ischemic Heart Diseases, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China; Key Laboratory of Viral Heart Diseases, National Health Commission, Shanghai, China.
Rongjun ZouDepartment of Cardiovascular Surgery, Guangdong Provincial Hospital of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, 510120, China.
Miyesaier AbudureyimuState Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; Cardiovascular Department, Shanghai Xuhui Central Hospital, Fudan University, Shanghai, 200031, China.
Junbo GeDepartment of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; National Health Commission (NHC) Key Laboratory of Ischemic Heart Diseases, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China; Key Laboratory of Viral Heart Diseases, National Health Commission, Shanghai, China.
Yingmei ZhangDepartment of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; National Health Commission (NHC) Key Laboratory of Ischemic Heart Diseases, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China; Key Laboratory of Viral Heart Diseases, National Health Commission, Shanghai, China. Electronic address: zhang.yingmei@zs-hospital.sh.cn.
Jun RenDepartment of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, China; National Health Commission (NHC) Key Laboratory of Ischemic Heart Diseases, Shanghai, China; National Clinical Research Center for Interventional Medicine, Shanghai, China; Key Laboratory of Viral Heart Diseases, National Health Commission, Shanghai, China. Electronic address: ren.jun@zs-hospital.sh.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAortic aneurysm/dissection (AAD) is a catastrophic vascular emergency with limited therapeutic options and poorly understood molecular underpinnings. Ferroptosis, an iron-dependent form of regulated cell death, emerged as a crucial driver of vascular degeneration although its pathological mechanisms in AAD remain largely undefined.

methodsWe integrated transcriptomic datasets to identify key dysregulated genes in AAD. PHB2 expression was examined by immunohistochemistry, immunofluorescence, and Western blotting in human tissues, murine models, and isolated vascular smooth muscle cells. Functional involvement of PHB2 was evaluated using VSMC-specific conditional knockout mice and AAV9-PHB2 overexpression in β-aminopropionitrile-evoked AAD model.

resultsTranscriptomic analysis revealed PHB2 as one of the most significantly downregulated genes in AAD, with selective suppression in VSMCs. Loss of PHB2 aggravated BAPN-induced aortic dilation, medial destruction, and elastic fiber fragmentation, whereas PHB2 overexpression preserved aortic wall integrity. RNAseq profiling implicated ferroptosis as the dominant pathway activated by PHB2 deficiency. Functionally, PHB2 overexpression mitigated Ang II-induced lipid ROS accumulation and Fe

conclusionWe identify a previously unrecognized PHB2-NEDD4L-NCOA4 regulatory axis that restrains ferroptosis in VSMCs and protects against AAD progression. Targeting this pathway may represent a promising therapeutic strategy for the prevention and treatment of AAD.

Indexed as

Aortic AneurysmAortic DissectionFerroptosisNedd4 Ubiquitin Protein LigasesNuclear Receptor CoactivatorsRepressor ProteinsAnimalsDisease Models, AnimalHumansMiceMice, KnockoutProhibitinsUbiquitinationNCOA4 protein, humanNcoA4 protein, mouseNedd4 Ubiquitin Protein LigasesNuclear Receptor CoactivatorsPHB2 protein, humanPhb2 protein, mouseProhibitinsRepressor ProteinsAortic dissectionFerroptosisNCOA4NEDD4LPHB2Ubiquitination

Identifiers

PMID41819783
PMCPMC12996198

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.